Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 8/20 | 0.37 |
| ▸ | MAOB | P27338 | 5/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.37 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15194685 | 1.00 | CYP2C9 (0.41) | CYP2C9CYP2C19MCL1LMNAKDM1A | |
| SCHEMBL15194679 | 0.88 | CYP2C9 (0.41) | CYP2C9CYP2C19MCL1LMNAKDM1A | |
| SCHEMBL2507229 | 0.85 | MEN1 (0.48) | MCL1LMNAHRH3FFAR1MEN1 | |
| SCHEMBL2507227 | 0.85 | MEN1 (0.48) | MCL1LMNAHRH3FFAR1MEN1 | |
| SCHEMBL1695729 | 0.85 | MEN1 (0.48) | MCL1LMNAHRH3FFAR1MEN1 | |
| SCHEMBL1695410 | 0.84 | TDP1 (0.43) | MCL1KDM1AHRH3FFAR1MEN1 | |
| SCHEMBL3115335 | 0.84 | GAA (0.40) | CYP2C9CYP2C19MCL1 | |
| SCHEMBL3115343 | 0.84 | GAA (0.40) | CYP2C9CYP2C19MCL1 | |
| SCHEMBL3115351 | 0.84 | GAA (0.40) | CYP2C9CYP2C19MCL1 | |
| SCHEMBL12151967 | 0.82 | SLC6A4 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571855-B1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-12-24 | — | — | EP | disclosed |
| US-8669252-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669252-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669252-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130217660-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-22 | — | — | US | disclosed |
| US-20130217660-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-22 | — | — | US | disclosed |
| US-20130217660-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-22 | — | — | US | disclosed |
| EP-2571855-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2012046771-A1 | CYCLOALKANE COMPOUND | アステラス製薬株式会社 (JP) | 2012-04-12 | — | — | WO | disclosed |
| WO-2011146300-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217660-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | CYP2C9 1027/4885CYP2C19 992/4885MCL1 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.